DRDirk Roymans

Dirk Roymans

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Dirk Roymans has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Anil Koul

    Janssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium

    3 shared publications
  • Eric Arnoult

    Computational Chemistry, Janssen R&D LLC, 1400 Mckean Road, Spring House, PA, 19477, USA

    3 shared publications
  • Bart Stoops

    DMPK, Janssen Research & Development, Janssen Pharmaceutica NV, Beerse, Belgium

    2 shared publications
  • Jean-François Bonfanti

    Tibotec, a division of Janssen-Cilag, Campus de Maigremont-BP615, F-27106 Val de Reuil Cedex, France

    2 shared publications
  • Marcia Van Ginderen

    Janssen Infectious Diseases and Vaccines, Janssen Pharmaceutica NV, Turnhoutseweg 30, 2340, Beerse, Belgium

    2 shared publications
  • Maxwell D. Cummings

    Tibotec-Virco Virology BVBA, Mechelen, Belgium

    2 shared publications

Latest Publications

  • Open Access

    Accelerating drug development using zebrafish disease models supported by pharmacokinetic-pharmacodynamic modeling as new approach methodology (NAM)

    by Gabriel Forn-Cuní, Bart van Lieshout, Bjørn Koch, Cristina Villellas, Stijn Van Asten, Dina Berlina, Ellen Lanckacker, Bart Stoops, Rob J. Vreeken, Dirk Roymans, et al.

    The development of novel therapeutics for infectious diseases remains a global health priority. To accelerate the treatment development, innovative strategies through new approach methodology (NAM) are needed to bridge speed of in vitro with predictive power of in vivo studies, while reducing mammalian experiments. The zebrafish ( Danio rerio ), particularly the embryo/larva, has been established as a valuable non-mammalian in vivo model in biomedical research. We developed a standardized and streamlined workflow for the zebrafish as NAM, which consisted of 3 steps: drug selection and efficacy evaluation, internal exposure assessment, and PKPD modelling. Compounds with higher tolerated doses than minimum inhibitory concentration were selected. Drug efficacy was quantified through longitudinal individual fluorescence microscopy at baseline and 24 and 48h on treatment. Drug exposure was quantified in larval homogenates and exposure medium from 0-48h on treatment. The PKPD relationship was quantified by non-linear mixed effects modelling. For case study bedaquiline, PKPD was quantified using a one-compartment model with age-depending elimination, and an Emax concentration-response relationship on the delayed logistic bacterial growth function, with an EC50 of 26.5 µg/mL and an Emax of 1.09-1.37. In the case of clarithromycin, in contrast, negligible internal exposure after waterborne treatment was observed, illustrating the risk of false negatives without internal exposure assessments. Bactericidal efficacy was confirmed by intravenous drug injections, showing a clear dose dependent antimycobacterial effect. The standardized zebrafish NAM workflow presented here facilitates the translation of drug efficacy to higher vertebrates, reducing rodent studies to confirmatory or replacing them completely, thus accelerating drug development. Study Highlights: What is the current knowledge on the topic?: There is an urgent need to accelerate development of anti-mycobacterial drugs while reducing preclinical rodent studies. The New Approach Methodologies (NAM) include non-mammalian in vivo experimental models, such as the phylogenetically lower vertebrate zebrafish ( Danio rerio ). Experiments in the zebrafish embryo (pre-hatching) or larva combine higher experimental throughput with lower ethical and resource constraints, while remaining predictive of higher vertebrates. What question did this study address?: How can the zebrafish embryo/larva experimental model, supported by pharmacokinetic-pharmacodynamic (PKPD) modelling, be leveraged as New Approach Methodology (NAM) to accelerate drug development in infectious diseases by bridging in vitro throughput with in vivo predictability. What does this study add to our knowledge?: We developed a standardized and streamlined workflow for the zebrafish as NAM, which consisted of 3 steps: drug selection and efficacy evaluation, internal exposure assessment, and PKPD modelling. Two anti-mycobacterial backbone drugs, bedaquiline and clarithromycin, were studied using the workflow. Bedaquiline dose-ranging PK and PD experiments supported quantification of the exposure-response relationship which approximated that in rodents. Clarithromycin, however, did not pass the workflow criteria, showing negligible internal exposure after waterborne treatment, illustrating the risk of false negatives without internal exposure assessments. How might this change clinical pharmacology or translational science?: The use of zebrafish experiments supported by PKPD modelling as NAM shows significant promise in drug development in infectious diseases. Our developed experimental and computational workflow enables characterization of a drug’s in vivo exposure-response within approximately 2 months. With the exposure-response, further development can be supported by prioritizing or de-risking drug(s) and by informing dose and design of confirmatory mammalian experiments, to accelerate the development of the most promising drugs to patients.


  • Open Access

    The methyltransferase domain of the Respiratory Syncytial Virus L protein catalyzes cap N7 and 2’-O-methylation

    by Priscila Sutto-Ortiz, Sergey Tcherniuk, Nina Ysebaert, Pravien Abeywickrema, Mathieu Noël, Alice Decombe, Françoise Debart, Jean-Jacques Vasseur, Bruno Canard, Dirk Roymans, et al.

    Respiratory syncytial virus (RSV) is a negative sense single-stranded RNA virus and one of the main causes of severe lower respiratory tract infections in infants and young children. RSV RNA replication/transcription and capping are ensured by the viral Large (L) protein. The L protein contains a polymerase domain associated with a polyribonucleotidyl transferase domain in its N-terminus, and a methyltransferase (MTase) domain followed by the C-terminal domain (CTD) enriched in basic amino acids at its C-terminus. The MTase-CTD of Mononegavirales forms a clamp to accommodate RNA that is subsequently methylated on the cap structure and depending on the virus, on internal positions. These enzymatic activities are essential for efficient viral mRNA translation into proteins, and to prevent the recognition of uncapped viral RNA by innate immunity sensors. In this work, we demonstrated that the MTase-CTD of RSV, as well as the full-length L protein in complex with phosphoprotein (P), catalyzes the N7- and 2’-O-methylation of the cap structure of a short RNA sequence that corresponds to the 5’ end of viral mRNA. Using different experimental systems, we showed that the RSV MTase-CTD methylates the cap structure with a preference for N7-methylation as first reaction. However, we did not observe cap-independent internal methylation, as recently evidenced for the Ebola virus MTase. We also found that at μM concentrations, sinefungin, a S-adenosylmethionine analogue, inhibits the MTase activity of the RSV L protein and of the MTase-CTD domain. Altogether, these results suggest that the RSV MTase domain specifically recognizes viral RNA decorated by a cap structure and catalyzes its methylation, which is required for translation and innate immune system subversion.


  • Open Access

    Development of a Stable Respiratory Syncytial Virus Pre-Fusion Protein Powder Suitable for a Core-Shell Implant with a Delayed Release in Mice: A Proof of Concept Study

    by Max Beugeling, Katie Amssoms, Freek Cox, Ben De Clerck, Ellen Van Gulck, Jeroen A. Verwoerd, Guenter Kraus, Dirk Roymans, Lieven Baert, Henderik W. Frijlink, et al.

    Currently, there is an increasing interest to apply pre-fusion (pre-F) protein of respiratory syncytial virus (RSV) as antigen for the development of a subunit vaccine. A pre-F-containing powder would increase the flexibility regarding the route of administration. For instance, a pre-F-containing powder could be incorporated into a single-injection system releasing a primer, and after a lag time, a booster. The most challenging aspect, obtaining the booster after a lag time, may be achieved by incorporating the powder into a core encapsulated by a nonporous poly(dl-lactic-co-glycolic acid) (PLGA) shell. We intended to develop a stable freeze-dried pre-F-containing powder. Furthermore, we investigated whether incorporation of this powder into the core-shell implant was feasible and whether this system would induce a delayed RSV virus-neutralizing antibody (VNA) response in mice. The developed pre-F-containing powder, consisting of pre-F in a matrix of inulin, HEPES, sodium chloride, and Tween 80, was stable during freeze-drying and storage for at least 28 days at 60 °C. Incorporation of this powder into the core-shell implant was feasible and the core-shell production process did not affect the stability of pre-F. An in vitro release study showed that pre-F was incompletely released from the core-shell implant after a lag time of 4 weeks. The incomplete release may be the result of pre-F instability within the core-shell implant during the lag time and requires further research. Mice subcutaneously immunized with a pre-F-containing core-shell implant showed a delayed RSV VNA response that corresponded with pre-F release from the core-shell implant after a lag time of approximately 4 weeks. Moreover, pre-F-containing core-shell implants were able to boost RSV VNA titers of primed mice after a lag time of 4 weeks. These findings could contribute to the development of a single-injection pre-F-based vaccine containing a primer and a booster.


  • A small-molecule fusion inhibitor of influenza virus is orally active in mice

    by Maria J. P. van Dongen, Rameshwar U. Kadam, Jarek Juraszek, Edward Lawson, Boerries Brandenburg, Frederike Schmitz, Wim B. G. Schepens, Bart Stoops, Harry A. van Diepen, Mandy Jongeneelen, et al.

    A small molecule that targets influenza: Many of us rely on seasonal vaccines for protection against influenza and are only too aware of their limited breadth. Broadly neutralizing antibodies (bnAbs) that target the conserved hemagglutinin (HA) stem of the influenza virus provide hope for the development of universal vaccines and are being evaluated in clinical trials. Van Dongen et al. selected and optimized a small-molecule lead compound that recapitulates key interactions of the bnAb with HA. Like the bnAb, the compound inhibited viral fusion in the endosomes of target cells. The compound protected mice from influenza after oral administration and neutralized virus infection in a 3D cell culture of human bronchial epithelial cells. Science , this issue p. eaar6221


  • Open Access

    Therapeutic efficacy of a respiratory syncytial virus fusion inhibitor

    by Dirk Roymans, Sarhad S Alnajjar, Michael B Battles, Panchan Sitthicharoenchai, Polina Furmanova-Hollenstein, Peter Rigaux, Joke Van Den Berg, Leen Kwanten, Marcia Van Ginderen, Nick Verheyen, et al.

    Respiratory syncytial virus is a major cause of acute lower respiratory tract infection in young children, immunocompromised adults, and the elderly. Intervention with small-molecule antivirals specific for respiratory syncytial virus presents an important therapeutic opportunity, but no such compounds are approved today. Here we report the structure of JNJ-53718678 bound to respiratory syncytial virus fusion (F) protein in its prefusion conformation, and we show that the potent nanomolar activity of JNJ-53718678, as well as the preliminary structure–activity relationship and the pharmaceutical optimization strategy of the series, are consistent with the binding mode of JNJ-53718678 and other respiratory syncytial virus fusion inhibitors. Oral treatment of neonatal lambs with JNJ-53718678, or with an equally active close analog, efficiently inhibits established acute lower respiratory tract infection in the animals, even when treatment is delayed until external signs of respiratory syncytial virus illness have become visible. Together, these data suggest that JNJ-53718678 is a promising candidate for further development as a potential therapeutic in patients at risk to develop respiratory syncytial virus acute lower respiratory tract infection.


  • Small-molecule Inhibition of Respiratory Syncytial Virus Fusion: It Takes Two to Tango

    by Dirk Roymans, Eric Arnoult, Maxwell D. Cummings, Anil Koul, Koen Andries

  • Binding of a potent small-molecule inhibitor of six-helix bundle formation requires interactions with both heptad-repeats of the RSV fusion protein

    by Dirk Roymans, Hendrik L. De Bondt, Eric Arnoult, Peggy Geluykens, Tom Gevers, Marcia Van Ginderen, Nick Verheyen, Hidong Kim, Rudy Willebrords, Jean-François Bonfanti, et al.

    Six-helix bundle (6HB) formation is an essential step for many viruses that rely on a class I fusion protein to enter a target cell and initiate replication. Because the binding modes of small molecule inhibitors of 6HB formation are largely unknown, precisely how they disrupt 6HB formation remains unclear, and structure-based design of improved inhibitors is thus seriously hampered. Here we present the high resolution crystal structure of TMC353121, a potent inhibitor of respiratory syncytial virus (RSV), bound at a hydrophobic pocket of the 6HB formed by amino acid residues from both HR1 and HR2 heptad-repeats. Binding of TMC353121 stabilizes the interaction of HR1 and HR2 in an alternate conformation of the 6HB, in which direct binding interactions are formed between TMC353121 and both HR1 and HR2. Rather than completely preventing 6HB formation, our data indicate that TMC353121 inhibits fusion by causing a local disturbance of the natural 6HB conformation.


    • 1 July 2009
      • Vol. 12  (4) , 479-87

    Prospects for the development of fusion inhibitors to treat human respiratory syncytial virus infection.

    by Jean-François Bonfanti, Dirk Roymans

    Human respiratory syncytial virus (hRSV) is a significant cause of respiratory illness in at-risk pediatric patients, immunocompromised adults and the elderly. No vaccine is currently available for the virus and treatment options are limited to the prophylactic treatment of at-risk infants with the mAb palivizumab (Synagis) and to therapeutic intervention with the nucleoside analog ribavirin (Rebetol). The clinical use of these agents is limited and a need exists for more effective treatment for the at-risk population. The merging of viral and cellular membranes is a crucial event in the hRSV life cycle that enables the virus to enter a host cell. The multistep fusion process is facilitated by the substantial refolding of a trimeric class I fusion protein (F protein), which is the main target of fusion inhibitors. Several small-molecule fusion inhibitors have been discovered, of which some have progressed significantly in the drug development process. BTA-9881 (Biota Holdings Ltd/MedImmune) and TMC-353121 (Johnson & Johnson) are the most advanced of this drug class. In addition, progress has been made in the development of next-generation antibodies such as motavizumab (Numax; MedImmune). This review will discuss the status and latest developments of compounds and antibodies that inhibit hRSV fusion.